ZENTALIS PHARMACEUTICALS INC (ZNTL)
Health Care · Clinical-stage oncology / biopharmaceuticals; WEE1 kinase inhibitors · NASDAQ
Zentalis is developing azenosertib, a first-in-class WEE1 inhibitor targeting Cyclin E1-positive ovarian cancer, with Phase 2/3 trials underway and accelerated approval potential.
What ZENTALIS PHARMACEUTICALS INC does
Zentalis is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), an investigational oral WEE1 inhibitor designed to target cancer cells with Cyclin E1 activation. The company is primarily focused on advancing azenosertib for Cyclin E1-positive platinum-resistant ovarian cancer (PROC), with Phase 2 and Phase 3 clinical trials ongoing. Azenosertib works by inhibiting WEE1, a DNA damage response kinase, forcing cancer cells into mitosis before they can repair DNA damage, leading to cell death.
Themes: ["Oncology / ovarian cancer","WEE1 inhibitors","Cyclin E1-positive tumors","Platinum-resistant ovarian cancer (PROC)","Biomarker-directed cancer therapy","DNA damage response / cell cycle control"]
Fundamentals
- Price$4.70 as of 2026-07-09 close
- Market cap$293M as of 2026-07-10
- 1-year return+282.7% as of 2026-07-09 close
- Net margin-246.0% as of 2026-07-10
- ROE-52.8% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta1.92 as of 2026-07-10
Key risks (from latest filing)
["Clinical development risk: azenosertib is still in Phase 2/3 trials with no approved products, and failure to achieve efficacy endpoints in DENALI Part 2 or ASPENOVA trials could prevent regulatory approval and product commercialization.","Regulatory approval uncertainty: accelerated approval pathway is dependent on FDA discretion and successful trial outcomes; even if approved, the Phase 3 ASPENOVA trial must achieve confirmatory efficacy data for conversion to full approval.","Limited market size and patient population: the addressable market for Cyclin E1-positive PROC is estimated at approximately 21,500 patients annually in key markets; failure to achieve rapid adoption or discover additional indications would constrain revenue potential."]
Competitors & peers
- Genmab (mirvetuximab folate receptor targeting for PROC)
- AstraZeneca (PARP inhibitors and other ovarian cancer therapeutics)
- Roche (bevacizumab and other ovarian cancer treatments)
- Genentech (ovarian cancer therapies)
- Tesaro / GSK (ovarian cancer drug developers)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.